Introduction
Materials and methods
Patients
Assessment of free DNA concentrations
Statistical analyses
Results
General clinical information of patients
Variables | Values |
---|---|
Age (mean ± SD (range)) | 59.79 ± 11.65 (34–84) |
Cell free DNA concentration—MN Kit (mean ± SD (range)) (ng/ml) | 13.92 ± 4.11 (3.6–22.3) |
Cell free tumor DNA—QIAGEN Kit (mean ± SD (range)) (ng/ml) | 19.1 ± 6.03 (6.1–32.6) |
Recurrence after (month) (mean ± SD (range)) | 7.76 ± 5.4 (1–19) |
Gender | |
Male | 45.5% |
Female | 54.5% |
Smoking | |
Yes | 22.7% |
No | 77.3% |
Stage | |
II | 2.3% |
III | 4.5% |
IV | 93.2% |
Recurrence | |
Yes | 56.8% |
No | 43.2% |
Current status | |
Alive | 67.6% |
Dead | 32.4% |
Metastasis | |
Non metastatic | 11.4% |
Metastasis to one organ | 68.1% |
Metastasis to two organ | 9.1% |
Metastasis to three organ | 11.4% |
Comparison of circulating free DNA concentrations as detected by two methods
Association between circulating free DNA concentration and patients’ characteristics
cfDNA concentration (MN kit) (ng/ml) | P value | cfDNA concentration (QIAGEN kit) (ng/ml) | P value | |
---|---|---|---|---|
Gender | ||||
Male vs. female | 13.96 (4.67) vs. 13.88 (3.69) | 0.94 | 19.21 (6.59) vs. 19.01 (5.67) | 0.91 |
Smoking | ||||
Yes vs. no | 13.96 (4.55) vs. 13.9 (4.05) | 0.97 | 19.17 (6.1) vs. 19.08 (6.1) | 0.96 |
Current status | ||||
Alive vs. dead | 13.22 (4.56) vs. 16.21 (3.4) | 0.05 | 17.56 (5.78) vs. 23.49 (6.28) | 0.007 |
Recurrence | ||||
Yes vs. no | 15.81 (3.45) vs. 12.06 (4.7) | 0.008 | 21.93 (6.09) vs. 16.27 (5.7) | 0.007 |
Stage | ||||
II and III vs. IV | 7.66 (2.5) vs. 14.37 (3.84) | 0.005 | 11.43 (2.05) vs. 19.66 (5.84) | 0.02 |
Metastasis | ||||
Non metastatic vs. Metastasis to one organ | 7.94 (3.81) vs. 13.69 [3] | 0.02 | 11.1 (3.52) vs. 18.71 (4.73) | 0.01 |
Non metastatic vs. Metastasis to two organs | 7.94 (3.81) vs. 16.5 (2.29) | 0.001 | 11.1 (3.52) vs. 23.5 (4.98) | 0.002 |
Non metastatic vs. Metastasis to three organ | 7.94 (3.81) vs. 19.18 (3.45) | < 0.001 | 11.1 (3.52) vs. 25.92 (6.24) | < 0.001 |
Metastasis to one organ vs. Metastasis to two organs | 13.69 [3] vs. 16.5 (2.29) | 0.33 | 18.71 (4.73) vs. 23.5 (4.98) | 0.26 |
Metastasis to one organ vs. Metastasis to three organs | 13.69 [3] vs. 19.18 (3.45) | 0.004 | 18.71 (4.73) vs. 25.92 (6.24) | 0.01 |
Metastasis to two organs vs. Metastasis to three organs | 16.5 (2.29) vs. 19.18 (3.45) | 0.57 | 23.5 (4.98) vs. 25.92 (6.24) | 0.87 |
cfDNA concentration (MN kit) (ng/ml) | cfDNA concentration (QIAGEN kit) (ng/ml) | |||
---|---|---|---|---|
R | P value | R | P value | |
Age | − 0.23 | 0.06 | − 0.18 | 0.12 |
Recurrence time | − 0.05 | 0.4 | − 0.19 | 0.2 |
ROC curve analysis
Differentiation of recurrence probability | Differentiation of metastatic potential | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Estimate criterion | AUC | Ja | Sensitivity | Specificity | P-valueb | Estimate criterion | AUC | Ja | Sensitivity | Specificity | P-valueb | |
MN | > 11.3 | 0.71 | 0.43 | 100 | 43.7 | 0.01 | > 10.1 | 0.98 | 0.95 | 95 | 100 | < 0.001 |
QIAGEN | > 15.1 | 0.74 | 0.5 | 100 | 50 | 0.004 | > 13 | 0.98 | 0.97 | 97.5 | 100 | < 0.001 |